Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.

Krina K PatelJatin J ShahLei FengHans C LeeElisabet M ManasanchJasper OlsemAshley MorpheyXiao Jiao HuoSheeba K ThomasQaiser BashirMuzaffar H QazilbashDonna M WeberRobert Z Orlowski

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The addition of ixazomib to lenalidomide maintenance demonstrated a better than expected PFS compared with historical data using lenalidomide alone and was safe and tolerable.

Keyphrases

multiple myeloma
newly diagnosed
stem cell transplantation
chronic lymphocytic leukemia
electronic health record
stem cells
machine learning
high dose